**Percentage HScore confirms low incidence of secondary haemophagocytic lymphohistiocytosis in hospitalised COVID-19 patients**

Michael R Ardern-Jones1,2, Matt Stammers2,4, Hang T.T. Phan3,4, Florina Borca3,4, Anastasia Koutalopoulou2, Ying Teo2, James Batchelor3,4, Trevor Smith2, Andrew S Duncombe5

1Clinical Experimental Sciences, University of Southampton Faculty of Medicine, Mailpoint 825, Level F, South Block, Sir Henry Wellcome Laboratories, Southampton General Hospital, Southampton, SO16 6YD, United Kingdom

2Division of Medicine, University Hospitals Southampton NHS Foundation Trust, Southampton General Hospital, Southampton, SO16 6YD, United Kingdom

3NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK

4Clinical Informatics Research Unit Faculty of Medicine, University of Southampton, Southampton, UK

5Department of Haematology, University Hospitals Southampton NHS Foundation Trust, Southampton, SO16 6YD, UK

Corresponding author: Michael Ardern-Jones

Tel: +44 (023) 81207594 E-mail: m.aj@soton.ac.uk

Article Type: Brief Report Running head: COVID HLH

Keywords: Hyperinflammation, SARS-CoV-2, HScore, %HScore, secondary haemophagocytic lymphohistiocytosis, COVID-19

Supplementary Table: 1

Authors Declaration:

No financial support or other benefits from commercial sources for the work reported on in the manuscript, or any other financial interests are declared. No potential conflict of interest or the appearance of a conflict of interest with regard to the work declared.

|  |  |  |
| --- | --- | --- |
| **Parameter** | **HScore points (criteria)** | **%HScore points (criteria)****(Minimum variables ≥3)** |
| Temperature (°C) | 0 (<38.4), 33 (38.4–39.4), or 49 (>39.4) | 0 (<38.4), 33 (38.4–39.4), or 49 (>39.4) |
| No. of cytopenias\* | 0 (1 lineage), 24 (2 lineages), or 34 (3 lineages) | 0 (1 lineage), 24 (2 lineages), or 34 (3 lineages) |
| Ferritin (μg/L) | 0 (<2,000), 35 (2,000–6,000), or 50 (>6,000) | 0 (<2,000), 35 (2,000–6,000), or 50 (>6,000) |
| Triglyceride (mmol/L) | 0 (<1.5), 44 (1.5–4), or 64 (>4) | 0 (<1.5), 44 (1.5–4), or 64 (>4) |
| Fibrinogen (g/L) | 0 (>2.5) or 30 (≤2.5) | 0 (>2.5) or 30 (≤2.5) |
| AST/ALT (IU/L) | 0 (<30) or 19 (≥30) | 0 (<30) or 19 (≥30) |
| Hemophagocytosis \*\* | 0 (no) or 35 (yes) | - |
| Immunosuppression | 0 (no) or 18 (yes) | - |
| Hepatomegaly / Spelnomegaly | 0 (none), 23 (either), or 38 (both) | - |
| **Score** | **Sum of points above (maximum 337)** | **Sum of points above / maximum score (maximum 100%)** |

Supplementary Table 1. HScore and %HScore parameters.

Table to show the differences in between HScore (1) and %HScore.

\*haemoglobin ≤92 g/L and/or WBC ≤5 x 109/L and/or platelets ≤110 x 109/L

\*\*features on bone marrow aspirate

AST, Aspartate Transaminase; ALT, Alanine aminotransferase; IU, International Units

1. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis & Rheumatology. 2014;66(9):2613-20.